Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Takuro, Hisanaga"'
Autor:
Keisuke Kakisaka, Nobuaki Nakayama, Kotaro Kumagai, Takuro Hisanaga, Takayuki Kondo, Toru Setsu, Shunsuke Sato, Yohei Kooka, Kei Endo, Yuichi Yoshida, Takayoshi Oikawa, Hidekatsu Kuroda, Akio Miyasaka, Ryuzo Abe, Taka-aki Nakada, Yoshihiro Ikura, Kenichi Harada, Takuya Genda, Shuji Terai, Naoya Kato, Taro Takami, Akio Ido, Satoshi Mochida, Takayuki Matsumoto, Atsushi Tanaka
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 4, Pp 497-504 (2023)
Background and Aims: Acute liver injury (ALI) due to autoimmune hepatitis (AIH) can be treated by immunosuppression. In contrast, idiosyncratic drug-induced liver injury (DILI) had a poor prognosis. DILI thus needs to be distinguished from non-DILI.
Externí odkaz:
https://doaj.org/article/41e7930ab9084fc1bab5aaa463fc1040
Autor:
Takuro Hisanaga, Isao Hidaka, Isao Sakaida, Nobuaki Nakayama, Akio Ido, Naoya Kato, Yasuhiro Takikawa, Kazuaki Inoue, Masahito Shimizu, Takuya Genda, Shuji Terai, Hirohito Tsubouchi, Hajime Takikawa, Satoshi Mochida, Intractable Hepato‐Biliary Disease Study Group of Japan
Publikováno v:
JGH Open, Vol 5, Iss 4, Pp 428-433 (2021)
Abstract Background and Aim In Japan, corticosteroids have been commonly used as a part of multidisciplinary therapy for patients with acute liver failure and late‐onset hepatic failure. However, there is controversy regarding the development of in
Externí odkaz:
https://doaj.org/article/0d4366d872a644fdb3f7e6e505aa7ffc
Autor:
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218136 (2019)
AimSorafenib is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, hepatic arterial infusion chemotherapy (HAIC) has also gained acceptance, but only in Japan. We explored the role of body composition as a factor aff
Externí odkaz:
https://doaj.org/article/42c369da1eae45cfadd131852c4b00bd
Autor:
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono, Maiko Nishi, Isao Hidaka, Shinya Kuwashiro, Shogo Shiratsuki, Keiji Matsuura, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Takashi Oono, Takuro Hisanaga, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takahiro Yamasaki, Taro Takami
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 2927
Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba62a4db059ea4b2dd78fd497687f3a4
Autor:
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida
Publikováno v:
Applied Sciences, Vol 11, Iss 4, p 1882 (2021)
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a
Externí odkaz:
https://doaj.org/article/b213dda1a9c04699bbb481c329b4615e
Autor:
Yurika Kotoh, Issei Saeki, Takahiro Yamasaki, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Publikováno v:
Applied Sciences, Vol 10, Iss 16, p 5403 (2020)
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore,
Externí odkaz:
https://doaj.org/article/b3b9f4a41694455eb0bc96deb80ae6c9
Autor:
Takashi Oono, Reo Kawano, Isao Hidaka, Tsuyoshi Ishikawa, Takahiro Yamasaki, Miyuki Masui, Toshihiko Matsumoto, Aki Fujinaga, Takuro Hisanaga, Taro Takami, Isao Sakaida, Issei Saeki, Yoshio Marumoto
Publikováno v:
Kanzo. 62:448-455
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5505502fd0c37aad85462a443234a327
https://doi.org/10.2957/kanzo.62.448
https://doi.org/10.2957/kanzo.62.448
Publikováno v:
Yamaguchi Medical Journal. 68:75-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f2dcb6ff73299dcc714ff73fdac9573
https://doi.org/10.2342/ymj.68.75
https://doi.org/10.2342/ymj.68.75
Autor:
Isao Hidaka, Masaki Maeda, K. Matsuura, Isao Sakaida, Toshihiko Matsumoto, Issei Saeki, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takuro Hisanaga
Publikováno v:
Transplantation Proceedings. 51:925-935
Objectives Liver transplantation remains the only curative therapy for decompensated liver cirrhosis. However, it has several limitations, and not all patients can receive liver transplants. Therefore, liver regenerative therapy without liver transpl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eb5afd5820c4b8edca41f5502f0f969
https://doi.org/10.1016/j.transproceed.2019.03.011
https://doi.org/10.1016/j.transproceed.2019.03.011
Autor:
Taro Takami, Takashi Oono, Issei Saeki, Isao Hidaka, Takahiro Yamasaki, Norikazu Tanabe, Ryo Sasaki, Takashi Matsuda, Isao Sakaida, Yurika Kotoh-Yamauchi, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takuro Hisanaga, Yutaka Suehiro
Publikováno v:
Applied Sciences, Vol 11, Iss 1882, p 1882 (2021)
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63a1cbcea9fd9c7f95bc0a074febc8df
https://www.mdpi.com/2076-3417/11/4/1882
https://www.mdpi.com/2076-3417/11/4/1882